Virpax Pocfratio vs Pe Ratio Analysis

VRPX Stock

USD 0.46 0.02 4.17%

Virpax Pharmaceuticals financial indicator trend analysis is much more than just breaking down Virpax Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Virpax Pharmaceuticals is a good investment. Please check the relationship between Virpax Pharmaceuticals Pocfratio and its Pe Ratio accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virpax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.

Pocfratio vs Pe Ratio

Pocfratio vs Pe Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Virpax Pharmaceuticals Pocfratio account and Pe Ratio. At this time, the significance of the direction appears to have totally related.

The correlation between Virpax Pharmaceuticals' Pocfratio and Pe Ratio is 1.0. Overlapping area represents the amount of variation of Pocfratio that can explain the historical movement of Pe Ratio in the same time period over historical financial statements of Virpax Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Virpax Pharmaceuticals' Pocfratio and Pe Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pocfratio of Virpax Pharmaceuticals are associated (or correlated) with its Pe Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pe Ratio has no effect on the direction of Pocfratio i.e., Virpax Pharmaceuticals' Pocfratio and Pe Ratio go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Pocfratio

Pe Ratio

Most indicators from Virpax Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Virpax Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virpax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.At this time, Virpax Pharmaceuticals' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.34 in 2024, whereas Selling General Administrative is likely to drop slightly above 6.1 M in 2024.

Virpax Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue	Inventory
Total Assets		0.64	0.37	0.3	0.97	0.79	-1.0	-0.56	0.49	1.0	1.0	0.45	-0.56	-0.65	0.97	0.85	0.26	0.96	0.02	1.0	0.79	0.97	0.02	0.79	-0.73	-0.21
Short Long Term Debt Total	0.64		0.71	0.71	0.49	0.73	-0.62	-0.76	0.4	0.64	0.64	0.82	-0.96	-0.25	0.56	0.82	0.83	0.5	0.39	0.64	0.41	0.5	0.39	0.41	-0.91	-0.38
Other Current Liab	0.37	0.71		0.99	0.12	0.81	-0.34	-0.94	-0.08	0.37	0.37	0.95	-0.67	-0.49	0.29	0.68	0.86	0.11	0.33	0.37	-0.11	0.13	0.33	-0.11	-0.73	-0.9
Total Current Liabilities	0.3	0.71	0.99		0.06	0.76	-0.28	-0.91	-0.14	0.31	0.31	0.94	-0.69	-0.4	0.23	0.63	0.88	0.05	0.41	0.3	-0.17	0.06	0.41	-0.17	-0.7	-0.89
Total Stockholder Equity	0.97	0.49	0.12	0.06		0.63	-0.97	-0.35	0.55	0.97	0.97	0.24	-0.4	-0.58	0.96	0.74	0.06	1.0	-0.09	0.97	0.88	1.0	-0.09	0.88	-0.58	0.03
Net Tangible Assets	0.79	0.73	0.81	0.76	0.63		-0.78	-0.94	0.24	0.79	0.79	0.82	-0.63	-0.8	0.69	0.95	0.63	0.61	0.16	0.79	0.41	0.63	0.16	0.41	-0.8	-0.68
Net Debt	-1.0	-0.62	-0.34	-0.28	-0.97	-0.78		0.55	-0.51	-1.0	-1.0	-0.44	0.53	0.66	-0.97	-0.86	-0.24	-0.97	0.01	-1.0	-0.81	-0.97	0.01	-0.81	0.71	0.18
Retained Earnings	-0.56	-0.76	-0.94	-0.91	-0.35	-0.94	0.55		-0.15	-0.57	-0.57	-0.92	0.68	0.67	-0.44	-0.87	-0.8	-0.34	-0.24	-0.56	-0.18	-0.35	-0.24	-0.18	0.8	0.78
Accounts Payable	0.49	0.4	-0.08	-0.14	0.55	0.24	-0.51	-0.15		0.5	0.5	-0.01	-0.33	-0.21	0.37	0.43	0.03	0.56	-0.31	0.49	0.83	0.56	-0.31	0.83	-0.55	0.35
Cash	1.0	0.64	0.37	0.31	0.97	0.79	-1.0	-0.57	0.5		1.0	0.45	-0.56	-0.65	0.97	0.86	0.26	0.96	0.02	1.0	0.8	0.97	0.02	0.8	-0.73	-0.21
Cash And Short Term Investments	1.0	0.64	0.37	0.31	0.97	0.79	-1.0	-0.57	0.5	1.0		0.45	-0.56	-0.65	0.97	0.86	0.26	0.96	0.02	1.0	0.8	0.97	0.02	0.8	-0.73	-0.21
Common Stock Total Equity	0.45	0.82	0.95	0.94	0.24	0.82	-0.44	-0.92	-0.01	0.45	0.45		-0.73	-0.48	0.38	0.78	0.95	0.23	0.29	0.45	0.0	0.24	0.29	0.0	-0.78	-0.73
Common Stock Shares Outstanding	-0.56	-0.96	-0.67	-0.69	-0.4	-0.63	0.53	0.68	-0.33	-0.56	-0.56	-0.73		0.06	-0.49	-0.68	-0.75	-0.42	-0.59	-0.55	-0.35	-0.41	-0.59	-0.35	0.83	0.4
Non Current Liabilities Total	-0.65	-0.25	-0.49	-0.4	-0.58	-0.8	0.66	0.67	-0.21	-0.65	-0.65	-0.48	0.06		-0.57	-0.73	-0.23	-0.55	0.38	-0.65	-0.38	-0.57	0.38	-0.38	0.48	0.48
Other Current Assets	0.97	0.56	0.29	0.23	0.96	0.69	-0.97	-0.44	0.37	0.97	0.97	0.38	-0.49	-0.57		0.75	0.18	0.96	0.01	0.97	0.72	0.96	0.01	0.72	-0.64	-0.17
Other Stockholder Equity	0.85	0.82	0.68	0.63	0.74	0.95	-0.86	-0.87	0.43	0.86	0.86	0.78	-0.68	-0.73	0.75		0.64	0.73	0.09	0.85	0.6	0.74	0.09	0.6	-0.85	-0.43
Total Liab	0.26	0.83	0.86	0.88	0.06	0.63	-0.24	-0.8	0.03	0.26	0.26	0.95	-0.75	-0.23	0.18	0.64		0.05	0.31	0.25	-0.09	0.06	0.31	-0.09	-0.74	-0.58
Net Invested Capital	0.96	0.5	0.11	0.05	1.0	0.61	-0.97	-0.34	0.56	0.96	0.96	0.23	-0.42	-0.55	0.96	0.73	0.05		-0.08	0.96	0.89	1.0	-0.08	0.89	-0.58	0.05
Short Long Term Debt	0.02	0.39	0.33	0.41	-0.09	0.16	0.01	-0.24	-0.31	0.02	0.02	0.29	-0.59	0.38	0.01	0.09	0.31	-0.08		0.02	-0.14	-0.09	1.0	-0.14	-0.08	-0.33
Total Current Assets	1.0	0.64	0.37	0.3	0.97	0.79	-1.0	-0.56	0.49	1.0	1.0	0.45	-0.55	-0.65	0.97	0.85	0.25	0.96	0.02		0.79	0.97	0.02	0.79	-0.72	-0.21
Capital Stock	0.79	0.41	-0.11	-0.17	0.88	0.41	-0.81	-0.18	0.83	0.8	0.8	0.0	-0.35	-0.38	0.72	0.6	-0.09	0.89	-0.14	0.79		0.88	-0.14	1.0	-0.48	0.32
Net Working Capital	0.97	0.5	0.13	0.06	1.0	0.63	-0.97	-0.35	0.56	0.97	0.97	0.24	-0.41	-0.57	0.96	0.74	0.06	1.0	-0.09	0.97	0.88		-0.09	0.88	-0.58	0.03
Short Term Debt	0.02	0.39	0.33	0.41	-0.09	0.16	0.01	-0.24	-0.31	0.02	0.02	0.29	-0.59	0.38	0.01	0.09	0.31	-0.08	1.0	0.02	-0.14	-0.09		-0.14	-0.08	-0.33
Common Stock	0.79	0.41	-0.11	-0.17	0.88	0.41	-0.81	-0.18	0.83	0.8	0.8	0.0	-0.35	-0.38	0.72	0.6	-0.09	0.89	-0.14	0.79	1.0	0.88	-0.14		-0.48	0.32
Current Deferred Revenue	-0.73	-0.91	-0.73	-0.7	-0.58	-0.8	0.71	0.8	-0.55	-0.73	-0.73	-0.78	0.83	0.48	-0.64	-0.85	-0.74	-0.58	-0.08	-0.72	-0.48	-0.58	-0.08	-0.48		0.45
Inventory	-0.21	-0.38	-0.9	-0.89	0.03	-0.68	0.18	0.78	0.35	-0.21	-0.21	-0.73	0.4	0.48	-0.17	-0.43	-0.58	0.05	-0.33	-0.21	0.32	0.03	-0.33	0.32	0.45

Click cells to compare fundamentals

Virpax Pharmaceuticals Account Relationship Matchups

Virpax Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	46.7K	465.4K	39.6M	19.7M	9.6M	12.7M
Other Current Liab	1.5M	3.1M	2.1M	3.1M	7.7M	8.1M
Total Current Liabilities	2.8M	3.7M	2.1M	3.1M	7.7M	8.1M
Total Stockholder Equity	(2.7M)	(4.2M)	37.5M	16.6M	1.9M	1.8M
Net Debt	1.2M	1.5M	(36.8M)	(19.0M)	(9.1M)	(9.6M)
Retained Earnings	(6.3M)	(10.6M)	(22.7M)	(44.4M)	(59.5M)	(56.6M)
Accounts Payable	3.5	22.1K	19.8K	37.6K	18.46	17.54
Cash	41.5K	54.8K	36.8M	19.0M	9.1M	11.9M
Cash And Short Term Investments	41.5K	54.8K	36.8M	19.0M	9.1M	11.9M
Common Stock Shares Outstanding	521.5K	494.5K	1.2M	1.2M	1.2M	1.3M
Liabilities And Stockholders Equity	46.7K	465.4K	39.6M	19.7M	9.6M	12.7M
Other Current Assets	467.0	18.3K	2.7M	678.4K	486.8K	720.0K
Other Stockholder Equity	3.6M	6.4M	60.2M	60.9M	61.5M	35.6M
Total Liab	2.8M	4.7M	2.1M	3.1M	7.7M	4.0M
Net Invested Capital	(1.5M)	(2.7M)	37.5M	16.6M	1.9M	1.8M
Total Current Assets	46.7K	73.1K	39.6M	19.7M	9.6M	12.7M
Net Working Capital	(2.7M)	(3.6M)	37.5M	16.6M	1.9M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Virpax Stock Analysis

When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Virpax Pocfratio vs Pe Ratio Analysis

Pocfratio vs Pe Ratio

Pocfratio vs Pe Ratio Correlation Analysis

Correlation Coefficient

Pocfratio

Pe Ratio

Virpax Pharmaceuticals fundamental ratios Correlations

Virpax Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Virpax Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Virpax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Net Working Capital	- 0.97	Net Debt
Net Invested Capital	- 0.97	Net Debt